Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 3 | -$1.33 | -$1.05 | -$1.20 |
Q2 2024 | 4 | -$1.44 | -$1.14 | -$1.31 |
Q3 2024 | 8 | -$1.52 | -$1.20 | -$1.38 |
Q4 2024 | 10 | -$1.65 | -$0.46 | -$0.96 |
Q1 2025 | 5 | -$1.40 | -$0.63 | -$0.91 |
Q2 2025 | 4 | -$0.65 | -$0.52 | -$0.59 |
Q3 2025 | 4 | -$0.34 | -$0.27 | -$0.31 |
Q4 2025 | 4 | $0.25 | $0.32 | $0.29 |
Q1 2026 | 3 | $0.03 | $0.04 | $0.04 |
Q2 2026 | 3 | $0.74 | $0.94 | $0.85 |
Q3 2026 | 3 | $1.34 | $1.70 | $1.54 |
Q4 2026 | 3 | $1.97 | $2.49 | $2.26 |
Axsome Therapeutics, Inc. last posted its earnings results on Tuesday, November 12th, 2024. The company reported $-1.34 earnings per share for the quarter, topping analysts' consensus estimates of $-1.38 by $0.04. The company had revenue of 104.76 M for the quarter and had revenue of 270.60 M for the year. Axsome Therapeutics, Inc. has generated $-5 earnings per share over the last year ($-5.27 diluted earnings per share) and currently has a price-to-earnings ratio of -13.47. Axsome Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 18th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/12/2024 | Q3 2024 | -$1.38 | -$1.34 | 0.04 | $98.37 M | $104.76 M |
08/05/2024 | Q2 2024 | -$1.30 | -$1.67 | -0.37 | $86.92 M | $87.17 M |
05/06/2024 | Q1 2024 | -$1.20 | -$1.44 | -0.24 | $75.00 M | |
02/23/2024 | Q4 2023 | -$2.08 | $71.53 M | |||
11/06/2023 | Q3 2023 | -$1.24 | -$1.32 | -0.08 | $54.87 M | $57.79 M |
08/07/2023 | Q2 2023 | -$1.24 | -$1.54 | -0.3 | $40.88 M | $46.70 M |
05/08/2023 | Q1 2023 | -$0.26 | $94.58 M | |||
02/27/2023 | Q4 2022 | -$1.54 | $24.37 M | |||
11/07/2022 | Q3 2022 | -$1.10 | -$1.13 | -0.03 | $16.64 M | $16.85 M |
08/09/2022 | Q2 2022 | -$1.19 | -$1.10 | 0.09 | $6.92 M | $8.82 M |
05/02/2022 | Q1 2022 | -$1.02 | -$1.07 | -0.05 | $0 | |
03/01/2022 | Q4 2021 | -$0.99 | -$0.90 | 0.09 | $0 | |
11/08/2021 | Q3 2021 | -$0.94 | -$0.93 | 0.01 | $0 | |
08/09/2021 | Q2 2021 | -$0.88 | -$0.86 | 0.02 | $0 | |
05/10/2021 | Q1 2021 | -$0.83 | -$0.78 | 0.05 | $0 | |
03/01/2021 | Q4 2020 | -$0.73 | -$0.78 | -0.05 | $0 | |
11/06/2020 | Q3 2020 | -$0.61 | $0 | |||
08/10/2020 | Q2 2020 | -$0.54 | -$0.49 | 0.05 | $0 | |
05/11/2020 | Q1 2020 | -$0.88 | $0 | |||
03/12/2020 | Q4 2019 | -$0.51 | -$0.71 | -0.2 | $0 |
Axsome Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 18th, 2025 based off last year's report dates.
In the previous quarter, Axsome Therapeutics, Inc. (:AXSM) reported $-1.34 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.38 by $0.04.
The conference call for Axsome Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Axsome Therapeutics, Inc.'s latest earnings report can be read online.
Axsome Therapeutics, Inc. (:AXSM) has a recorded annual revenue of $270.60 M.
Axsome Therapeutics, Inc. (:AXSM) has a recorded net income of $270.60 M. Axsome Therapeutics, Inc. has generated $-5.27 earnings per share over the last four quarters.
Axsome Therapeutics, Inc. (:AXSM) has a price-to-earnings ratio of -13.47 and price/earnings-to-growth ratio is 43.85.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED